<DOC>
	<DOCNO>NCT00102674</DOCNO>
	<brief_summary>The purpose study : - Evaluate tolerability two cangrelor regimen . - Compare PD cangrelor regimens oral clopidogrel .</brief_summary>
	<brief_title>Pharmacokinetics/Pharmacodynamics ( PK/PD ) Cangrelor</brief_title>
	<detailed_description>The purpose study : - To evaluate tolerability two cangrelor regimen bolus plus infusion ( A B ) . - To characterize pharmacokinetics Cangrelor ( A B ) . - To compare pharmacodynamics cangrelor regimens oral 600 mg dose clopidogrel ( A , B , C D ) . - To determine effect prior cangrelor treatment pharmacodynamics clopidogrel ( C D ) . - To determine effect prior clopidogrel treatment pharmacodynamics cangrelor ( Group D ) . - To determine effect concomitant clopidogrel cangrelor exposure pharmacodynamics clopidogrel ( Group D ) .</detailed_description>
	<mesh_term>Cangrelor</mesh_term>
	<criteria>Provide write informed consent initiation study related procedure . Age 18 55 year Normal finding physical examination . A normal 12lead ECG normal vital sign ( blood pressure , heart rate ) , unless abnormality consider clinically irrelevant investigator . Normal laboratory hematology value unless investigator consider abnormality clinically irrelevant . Negative test pregnancy determine urinary bHCG prior administration study drug female childbearing potential . Body Mass Index ( BMI ) 20 25 kg/m2 base actual body weight . A history presence renal , hepatic , neurological , hematological , gastrointestinal , psychiatric disease condition know interfere absorption , distribution , metabolism excretion drug . Hypersensitivity clopidogrel cangrelor ( excipients therein ) . Symptoms clinically significant illness , surgery trauma within 3 month prior screen . Donation blood plasma total 500 mL within 3 month preceeding study . A significant history alcohol drug abuse , positive urine drug screen , tobacco use within 3 month precede enrollment , alcohol ingestion within 48 hour dose . A history hepatitis human immunodeficiency virus ( HIV ) exposure thereto . Use prescribed medication 2 week prior dose , aspirin naproxencontaining medication within 2 week dose , use acetaminophen within 24 hour ibuprofen , vitamin dietary supplement within 48 hour dose ( oral contraceptive permit ) . Personal family history coagulation bleed disorder , reasonable suspicion vascular malformation , include aneurysm ; history important bleeding , ( i.e . hematemesis , rectal bleeding , melena , severe recurrent epistaxis , hemoptysis intracranial hemorrhage ) , history head injury intracerebral disease , recent plan spinal epidural puncture . Significant epigastric pain `` indigestion '' , either chronically within 4 week prior screen . Diagnosed hypertension , supine blood pressure 150/90 mmHG less 100/50 mmHg screening . Participation clinical study investigational new drug 3 month prior dose study participation study new formulation market drug previous 3 month . Anemia thrombocytopenia ( value screen hematology le report laboratory 's low limit normal ) . Any characteristic condition , opinion investigator , make participation study inappropriate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>cangrelor</keyword>
	<keyword>clopidogrel</keyword>
</DOC>